Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases

Neurology

Volumn 51, Issue 6 SUPPL. 5, 1998, Pages

  Dalakas, Marinos C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NEUTRALIZING ANTIBODY; SUPERANTIGEN;

ADULT; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; ASEPTIC MENINGITIS; AUTOIMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG MEGADOSE; DRUG SAFETY; HEMOLYSIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LYMPHOCYTE FUNCTION; MIGRAINE; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMYELINIZATION; RISK FACTOR; SKIN MANIFESTATION;

EID: 0032437420     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.51.6_suppl_5.s2     Document Type: Article

References (69)

1. Imbach P, d'Apuzzo V, Hirt A, Rossi E, Vest M, Barandun S, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1128-1131.
2. Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Ann Intern Med 1990;112:278-292.
3. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-116.
4. Dalakas MC. Intravenous immunoglobulin therapy for neurological diseases. Ann Intern Med 1997;126:721-730.
5. Gordon DS, guest ed. Innovative use of intravenous immunoglobulin in clinical hematology. Am J Med 1987;83(4A):1-56.
6. Jungi TW, Nydegger VE. Proposed mechanisms of action of intravenous IgG in autoimmune diseases. Transfus Sci 1992; 13:267-290.
7. Eibl MM, Wedgood RJ. Intravenous immunoglobulin: a review. Immunodefic Rev 1989;1(Suppl):1-42.
8. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994;44:223-226.
9. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-262.
10. Tankersley DL, Preston MS, Finlayson JS. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol 1988; 25:41-48.
11. Roux KH, Tankersley DL. A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 1990;144:1387-1392.
12. Varela F, Andersson A, Dietrich G, et al. The population dynamics of antibodies in normal and autoimmune individuals. Proc Natl Acad Sci USA 1991;88:5917-5921.
13. Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contains anti-idiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990;85:620-629.
14. Lecky BRF, ed. Gammaglobulin treatment in neurology. Fundamentals and clinical applications. J Neurol Neurosurg Psychiatry 1994;57(Suppl 1).
15. Kazatchkine MD, Dietrich G, Hurez, et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin. Immunol Rev 1994;139:79-107.
16. Uher F, Dickler HB. Cooperativity between B lymphocytes membrane molecules: independent ligand occupancy and crosslinking of antigen receptors and Fc gamma receptors downregulates B lymphocyte function. J Immunol 1986;137: 3124-3129.
17. Diegel M, Rankin B, Bolen J, Dubois P, Kiener P. Cross linking of Fc receptor to surface immunoglobulin on B cells provides an inhibitory signal that closes the plasma membrane calcium channel. J Biol Chem 1994;269:11409-11416.
18. Vassilev T, Gelin C, Kaveri SV, Xilber MT, Boumsell L, Kazatchkine MD. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993;92:369-372.
19. Dalakas MC. Experience with IVIg in the treatment of patients with myasthenia gravis. Neurology 1997;48S:64-69.
20. Motomura M, Bain PG, Misbah SA, et al. Effect of intravenous immunoglobulin (IVIg) treatment on anti-calcium channel antibody titres in the Lambert-Eaton myasthenic syndrome [abstract]. J Neurol 1995;242:S44.
21. Malik U, Oleksowicz L, Latov N, Cardo LJ. Intravenous γ-globulin inhibits binding of anti-GMI to its target antigen. Ann Neurol 1996;39:136-139.
22. Yuki N, Miyagi F. Possible mechanism of intravenous immunoglobulin treatment on anti-GM , antibody-mediated neuropathies. J Neurol Sci 1996;139:160-162.
23. Chaudhry V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol 1993;33:237-242.
24. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies. Neurology 1994;44:429-432.
25. Dalakas MC, Stein DP, Otero C, Sekul E, Cupler EJ, Mc-Crosky S. Effect of high-dose intravenous immunoglobulin (IVIg) on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol 1994;51:861-864.
26. Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996;40:792-795.
27. Svenson M, Hansen MB, Bendtzen K Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993;92:2533-2539.
28. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139:5-19.
29. Dalakas MC, Ilia I, Dambrosia JM, Soueidan SA, et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329:1993-2000.
30. Amemiya K, Dalakas MC. Cytokine mRNA expression in the muscle of patients with inclusion body myositis (IBM) before and after treatment with steroids and intravenous immunoglobulin [Abstract]. Neurology 1997;48:126.
31. Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol 1995;37(S)74-86.
32. Kekow J, Reinhold D, Pap T, Ansorge S. Intravenous immunoglobulins and transforming growth factor b. Lancet 1998;351: 184-185.
33. Basta M, Kirshbom P, Frank MM, Fries LF. Mechanisms of therapeutic effect of high-dose intravenous immunoglobulin. J Clin Invest 1989;84:1974-1981.
34. Dalakas MC. Polymyositis, dermatomyositis and inclusionbody myositis. N Engl J Med 1991;325:1487-1498.
35. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-1735.
36. Dalakas MC. Clinical relevance of IVIg in the modulation of the complement-mediated tissue damage: implications in dermatomyositis, Guillain Barré syndrome and myasthenia gravis. In: Kazatchkine M, Morel A, eds. Intravenous immunoglobulin research and therapy. London: Parthenon Publishing, 1996:89-93.
37. Dalakas MC. Experience with IVIg in the treatment of inflammatory myopathies. In: Kazatchkine M, Morel A., eds. Intravenous immunoglobulin research and therapy. London: Parthenon Publishing, 1996;275-284.
38. Basta M, Ilia I, Dalakas MC. Increased in vitro uptake of the complement C3b in the serum of patients with Guillain Barré syndrome, myasthenia gravis and dermatomyositis. J Neuroimmunol 1996;71:227-229.
39. Dalakas MC. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. Ann Neurol 1995;37(Suppl):2-13.
40. Kurlander RJ, Hall J. Comparison of intravenous gammaglobulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest 1986; 77:2010-2018.
41. Kurlander RJ. Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J CHn Invest 1980;66:773-781.
42. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB. Human autoantibodies reactive with synthetic autoantigens from T cell receptor 20 chain. Proc Natl Acad Sci USA 1992;89:3325-3329.
43. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory of activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993;91: 602-607.
44. Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve 1997;20:1102-1107.
45. Rigal D, Vermot-Desroches C, Heitz S, et al. Effect of IVIg in peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effect on LFA-1 and CD56 molecules. Clin Immunol Immunopathol 1994;71: 309-314.
46. Leung DYM, Burns JC, Newburger JW, Geha RS. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 1987;79:468-472.
47. Blasczyk R, Westhoff V, Grosse-Wilde H. Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341:789-790.
48. Kaveri S, Vassilev T, Hurex V, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996;97:868-869.
49. van Engelson BGM, Miller DJ, Pavelko KD, Hommes OR, Rodriguez M. Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis. J Neurol Neurosurg Psychiatry 1994; 57(Suppl):65-68.
50. Gabriel CM, Gregson NA, Redford EJ, Davies M, Smith KJ, Hughes RAC. Human immunoglobulin ameliorates rat experimental allergic neuritis. Brain 1997;120:1533-1540.
51. Newburger JW, Takahashi M, Berser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-1639.
52. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991;325: 110-117.
53. Woodruff RK, Griff AP, Firkin FL, Smith IL. Fatal thrombic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986;2:217-218.
54. Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992;42:257-258.
55. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 1994;44:1180-1181.
56. Hague RA, Eden DB, Yap PL, Mok JYO, Rae P. Hyperviscosity in HIV infected children: a potential hazard during intravenous immunoglobulin therapy. Blut 1990;61:66-67.
57. Voltz RV, Rosen F, Yousry T, Beck J, Hohlfeld R. Reversible encephalopathy with cerebral vasospasm in a GBS patient treated with IV immunoglobulin. Neurology 1996;46:250-251.
58. Constantinescu CS, Chang AP, McClusky LF. Recurrent migraine and intravenous immune globulin therapy. N Engl J Med 1993;329:583-584.
59. Dalakas MC. Aseptic meningitis and intravenous immunoglobulin. Ann Intern Med 1995;122:316-317.
60. Dalakas MC. Meningitis and skin reactions after intravenous immunoglobulin therapy. Ann Intern Med 1997;127:1130.
61. Chan-Lam D, Fitzsimmons EJ, Douglas WS. Alopecia after immunoglobulin infusion. Lancet 1982;1:1436.
62. Boom BW, Brand A, Bavinek JB, et al. Severe leukocytoclastic vasculitis of the skin in a patient with essential mixed cryoglobulinemia treated with high-dose immunoglobulin intravenously. Arch Dermatol 1988;124:1550-1553.
63. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. N Engl J Med 1986;314:560-564.
64. Björkander J, Hammarström L, Smith E, Buckley RH, Cunningham-Rundles C, Hanson LA. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 1987;7:8-15.
65. Ellie E, Combe C, Ferrer X. High-dose intravenous immune globulin and acute renal failure. N Engl J Med 1992;327: 1032-1033.
66. Asham N, Palmer BF, Wheeler D, et al. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med 1994;154:1985-1987.
67. Blick KE, Liles SM. Principles of clinical chemistry. New York: John Wiley & Sons, 1985:401-404.
68. Outbreak of hepatitis C associated with intravenous immunoglobulin administration, United States, October 1993 - June 1994. MMWR 1994;43:505-509.
69. Schiff RJ. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994;331:1649-1650.